Publicaciones en colaboración con investigadores/as de Charité (19)

2024

  1. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 10, pp. 2648-2668.e2

2023

  1. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

  2. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs

    Nature Reviews Drug Discovery, Vol. 22, Núm. 9, pp. 743-767

2022

  1. EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 1, pp. 17-38

2021

  1. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy

    Clinical and Translational Allergy, Vol. 11, Núm. 4

  2. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 648-676

  3. EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 4, pp. 988-1009

  4. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 45-58

  5. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 59-70

  6. What is the contribution of IgE to nasal polyposis?

    Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 6, pp. 1997-2008

2020

  1. Allergic rhinitis

    Nature Reviews Disease Primers, Vol. 6, Núm. 1

  2. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

    Allergologie, Vol. 43, Núm. 7, pp. 255-271

  3. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 11, pp. 2764-2774

  4. In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan—An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 9, pp. 2161-2169

2019

  1. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 5, pp. 855-873

  2. Prioritizing research challenges and funding for allergy and asthma and the need for translational research—The European Strategic Forum on Allergic Diseases

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 11, pp. 2064-2076

2018

  1. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 4, pp. 816-826

  2. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 1, pp. 64-76

2017

  1. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 72, Núm. 12, pp. 1825-1848